Pfizer Inks $865M Discovery Deal with Cartography Biosciences for Tumor-Selective Antigens

Pfizer announced a multiyear cancer discovery collaboration with Cartography Biosciences on January 6, 2026, potentially worth up to $865 million in biobucks plus tiered royalties168.

The deal includes up to $65 million in upfront, near-term milestone, and option exercise payments; Pfizer can opt into multiple antigens discovered by Cartography using its Atlas and Summit platforms1.

Cartography's platforms leverage datasets of hundreds of thousands of cell states from healthy individuals and tumor profiling to identify tumor-selective antigens in an undisclosed disease area1.

This follows Cartography's prior partnership with Gilead in 2024 for triple-negative breast cancer and non-small cell lung cancer, and recent FDA clearance for phase 1 trial of its lead T-cell engager CBI-1214 in colorectal cancer1.

Pfizer Ventures previously led Cartography's $67 million Series B financing in 2025 to advance CBI-1214 toward clinic12.

Sources:

1. https://www.fiercebiotech.com/biotech/pfizer-charts-course-tumor-selective-antigens-865m-cartography-collab

2. https://www.biospace.com/press-releases/cartography-secures-67-million-series-b-financing-to-advance-differentiated-oncology-pipeline-of-antibody-based-therapies-into-the-clinic

6. https://www.thepharmaletter.com/pharmaceutical/clarivate-flags-11-therapies-as-2026-drugs-to-watch

8. https://www.marketscreener.com/news/cartography-biosciences-and-pfizer-to-collaborate-on-the-discovery-of-tumor-selective-antigens-ce7e59dfdb89f323